key: cord-0700751-r9qtlix0
authors: Costa, Silvia Figueiredo; Buss, Lewis; Espinoza, Evelyn Patrícia Sanchez; Vieira, Jose Mauro; de Oliveira- da Silva, Lea Campos; de Souza, Regina Maia; Neto, Lauro Perdigão; Porto, Ana Paula Matos; Lazari, Carolina; dos Santos, Vera Aparecida; Duarte, Alberto; Nastri, Ana Catharina; da Costa Leite, Gabriel Fialkovitz; Manuli, Erika; de Oliveira, Maura Salaroli; Zampelli, Daniella Bosco; Pastore, Laerte; Segurado, Aluísio Cotrim; Levin, Anna S.; Sabino, Ester
title: Performance of a qualitative rapid chromatographic immunoassay to diagnose COVID-19 in inpatients in a middle-income country
date: 2020-08-14
journal: Journal of Clinical Virology
DOI: 10.1016/j.jcv.2020.104592
sha: 2f932a0db641e6e1774f7257f4677af10f0ddf5e
doc_id: 700751
cord_uid: r9qtlix0

Abstract Objectives We evaluated a rapid chromatographic immunoassay (IgG/IgM antibodies) and an ELISA assay to diagnose COVID-19 in inpatients at two Brazilian hospitals. Methods A total of 122 subjects with COVID-19 were included: 106 SARS-COV-2 RT-PCR-positive patients and 16 RT-PCR-negative patients with symptoms and chest computed tomography (CT) consistent with COVID-19. Ninety-six historical blood donation samples were used as controls. Demographic and clinical characteristics were retrieved from electronic records. Sensitivity and specificity were calculated, as were their 95% binomial confidence intervals using the Clopper-Pearson method. All analyses were performed in R version 3.6.3. Results The sensitivity of the chromatographic immunoassay in all RT-PCR-positive inpatients, irrespective of the timing of symptom onset, was 85.8% (95% binomial CI 77.7% to 91.9%). This increased with time after symptom onset, and at >14 days was 94.9% (85.9% to 98.9%). The specificity was 100% (96.4% to 100%). 15/16 (94%) RT- PCR-negative cases tested positive. The most frequent comorbidities were hypertension and diabetes mellitus and the most frequent symptoms were fever, cough, and dyspnea. All RT-PCR-negative patients had pneumonia. The most frequent thoracic CT findings were ground glass changes (n = 11, 68%), which were bilateral in 9 (56%) patients, and diffuse reticulonodular infiltrates (n = 5, 31%). Conclusions The COVID-19 rapid chromatographic immunoassay evaluated in this study had a high sensitivity and specificity using plasma, particularly after 14 days from symptom onset. ELISA and qualitative rapid chromatographic immunoassays can be used for the diagnosis of RT-PCR-negative patients.

The sensitivity of the chromatographic immunoassay in all RT-PCR-positive inpatients, irrespective of the timing of symptom onset, was 85.8% (95% binomial CI 77.7% to 91.9%). This increased with time after symptom onset, and at >14 days was 94.9% (85.9% to 98.9%). The specificity was 100% (96.4% to 100%). 15/16 (94%) RT-PCR-negative cases tested positive. The most frequent comorbidities were hypertension and diabetes mellitus and the most frequent symptoms were fever, cough, and dyspnea. All RT-PCR-negative patients had pneumonia. The most frequent thoracic CT findings were ground glass changes (n=11, 68%), which were bilateral in 9 (56%) patients, and diffuse reticulonodular infiltrates (n = 5, 31%). Conclusions The COVID-19 rapid chromatographic immunoassay evaluated in this study had a high sensitivity and specificity using plasma, particularly after 14 days from symptom onset. ELISA and qualitative rapid chromatographic immunoassays can be used for the diagnosis of RT-PCR-negative patients.

Keywords: SARS-cov-2; ELISA; qualitative rapid chromatographic immunoassays

Brazil is the epicenter of the COVID-19 pandemic in Latin America. As of 29 th May 2020, there had been 555,383 confirmed cases and 31,199 deaths [1-2]. There is little data on the use of serology assays for the investigation of patients with COVID-19 in Brazil [3] . The current gold standard for COVID-19 diagnosis is real-time reverse transcription polymerase chain reaction (RT-PCR) [4] [5] . The accuracy of this method depends on the viral load at the collection site and on time from symptom onset [4] [5] [6] .

Detection of antibodies, especially IgA and IgM, which are produced early after the onset of infection, may be an important tool when combined with RT-PCR to improve sensitivity and diagnostic accuracy [5] [6] [7] [8] [9] [10] . Several qualitative rapid chromatographic immunoassays (RCI) have been developed and used in different countries. However, the test characteristics vary widely, with reported sensitivities ranging from 20% to 93% [11] [12] .

The aim of this study was to evaluate an RCI (Wondfo-China) to diagnose COVID-19 in inpatients in two Brazilian hospitals. We further compared the results with those obtained with an ELISA (Euroimmun -Germany).

This is a prospective multicenter cohort of COVID-19 hospitalized patients at two Brazilian 

We included a group of hospitalized patients and healthcare workers (not requiring hospitalization) with a positive SARS-CoV-2 RT-PCR, as well as a group of patients with negative RT-PCR but a clinical COVID-19 diagnosis based on highly suggestive symptoms and chest computed tomography (CT) findings. Demographic and clinical characteristicsincluding age, sex, comorbidities and presenting symptomswere retrieved from electronic health records. The database was built using the Epi Info software (CDC, Atlanta, GA).

Respiratory samples were obtained from both the nasopharynx and oropharynx using rayon swabs. RNA was extracted from clinical samples with an automated method using magnetic beads (mSample Preparation System RNA, Abbott, Illinois, USA). SARS-CoV-2 RNA reverse transcription, amplification, and detection were performed using an adapted protocol, as described elsewhere [11] [12] . An assay detecting the E gene was used as the first-line screening tool, followed by confirmatory testing with an assay detecting the N gene.

We tested all patient and control samples using an ELISA (Euroimmun-Lübeck, Germany) that detects anti-SARS-CoV-2 IgA and IgG antibodies, as well as an RCI (Wondfo-China) that detects anti-SARS-CoV-2 IgG/IgM.

The ELISA assays, which detect anti-SARS-CoV-2 S1 IgG and IgA, were performed according to the manufacturer's protocol. We detected optical density (OD) at 450 nm and calculated a ratio of the reading of each sample to the reading of the calibrator (included in the kit). Results were interpreted according to the manufacturer's recommendation: a ratio <0.8 as negative, between 0.8 and 1.1 as borderline, and ≥1.1 as positive.

The qualitative RCI was performed using 10μL of serum or plasma, pipetted into the sample cavity of the test device. 2-3 drops of buffer solution (80μL) were added to the cavity below J o u r n a l P r e -p r o o f the sample cavity. The result was read in 15 minutes by three people that had received appropriate training. The color change was compared to the assay standard.

Specificity was calculated as the number of negative test results divided by the total number of negative samples tested. The sensitivity was the number of positive test results divided by the number of known-positive samples tested. 95% binomial confidence intervals were calculated using the Clopper-Pearson method. All analyses were performed in R version 3.6.3.

This study was approved by the Brazilian national ethics review board (CONEP), protocol number 30701920200000068. Table 1 . All RT-PCR-negative patients had pneumonia. The most frequent thoracic CT findings were ground glass changes (n=11, 68%), which were bilateral in 9 (56%) patients, and diffuse reticulonodular infiltrates (n = 5, 31%).

Six (38%) patients were intubated ( 

This is the first multicenter study conducted in a middle-income country to validate a qualitative rapid chromatographic immunoassay for the diagnosis of COVID-19. Our findings show that the Wondfo RCI, when used with plasma or serum, has a high sensitivity and J o u r n a l P r e -p r o o f specificity, especially after 14 days from symptom onset. Furthermore, the performance of the rapid test was superior to that of RT-PCR, as it detected 15 of 16 PCR-negative cases. RT-PCR is not usually available in low-resource settings, which makes the rapid test (using plasma or serum) suitable as an alternative diagnostic modality. However, it is important to note that RCIs such as the Wondfo assay may have a lower sensitivity (23% to 90%) when used with capillary blood [3; 9-10;16].

The Wondfo RCI detects SARS-CoV-2 IgG/IgM antibodies. Anti-SARS-CoV-2 antibodies present in the sample bind to recombinant antigens coated on colloidal gold particles and form an antigen-antibody/colloidal gold complex. Despite the high sensitivity using plasma or serum, a limitation of the assay is that it cannot differentiate acute disease from past infection.

Our study was conducted in patients with a wide spectrum of disease, including different age groups, periods from symptom onset and comorbidities. Our results show that serology assays are useful for diagnosing SARS-COV-2, even in PCR-negative patients where there is a strong suspicion of COVID-19 based on presenting symptoms and CT findings.

The Euroimmun ELISA has the advantage of being automated, and therefore can be performed on a large scale. Furthermore, it can differentiate the antibody class, such as IgA that becomes positive from the fifth symptomatic day [13] [14] . In contrast, the Wondfo RCIalbeit with the disadvantage of having to use plasma or serum to achieve a good sensitivitycan be used in primary care with results available within 15 minutes. However, it is important to note that both tests are most sensitive after 14 days of symptoms.

We found a high sensitivity and specificity for the Wondfo RCI for the diagnosis of COVID-19 using plasma samples. Sensitivity was highest after 14 days from symptom onset. ELISA and qualitative rapid chromatographic immunoassays can also be used for the diagnosis of RT-PCR-negative patients. 

-Coronavirus disease 2019 (COVID-19) Situation Report -136 2020

Sensitivity of the Wondfo One Step COVID-19 test using serum samples

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Report from the American Society for Microbiology COVID-19 International Summit

Molecular and serological investigation of 2019-nCov infected patients: implication of multiple shedding routes

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Members of the San Matteo Pavia COVID-19 Task Force. Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease

IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study

Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil

The authors declare that they have no competing interests.

Internal funding from the Hospital das Clínicas of University of São Paulo, Brazil.